Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


LSP Leads Financing Round in Insulin Pump Company ViCentra

Amsterdam, the Netherlands, 20 January 2016. LSP (Life Sciences Partners), a leading European investor in health care, announces its investment in the Series B Round of ViCentra B.V., a private Dutch company commercializing the Kaleido insulin pump system for diabetes patients. The syndicate, led by LSP with participation from existing investor INKEF will invest EUR 10 million. The funding will support European commercialization of the Kaleido system and preparations for US market entry. As part of the financing, Anne Portwich and Jörg Neermann, both partners, LSP, will join ViCentra’s supervisory board.

Driven by ViCentra’s belief in the power of innovative healthcare products that put the people who use them first and a desire to be meaningfully different, Kaleido aims to reduce the impact that diabetes can have on daily life. Utilizing Bluetooth wireless technology, Kaleido will infuse color and choice into the market, networking its hybrid patch pumps and handsets into a broader family of easy-to-use products and data services to create a customer-focused, integrated diabetes support service. Setting its sights on expanding insulin pump usage by appealing to both first time and experienced insulin pump users, Kaleido will launch in selected European territories over the course of 2016.

About ViCentra
ViCentra was founded in 2013 with investments from Dutch investors Health Innovations and INKEF. Based in Utrecht, the Netherlands, ViCentra brings together a team of people that believe in keeping things simple. That if products are simple, look beautiful and deliver superb results, they’ll be more enjoyable to use and more likely to help people achieve great things. ViCentra are creating healthcare products with this philosophy firmly in mind. We don’t design for patients – we design for people. More information can be found at and

About LSP
LSP (Life Sciences Partners) is a leading independent European investment firm, providing financing for private and public life-science companies. Since the late 1980s, LSP’s management has invested in a large number of highly innovative enterprises, many of which have grown to become leaders of the global life-science industry. With over EUR 1 billion of investment capital raised to date and offices in Amsterdam, Munich and Boston, LSP is one of Europe’s largest and most experienced specialist life-science investors. LSP will participate with two funds in this financing, the LSP Health Economics Fund and the LSP 5 Fund. For more information, please visit

Anne Portwich, PhD
Partner LSP
+31 20 6645500

Publisher Contact Information:

Life Sciences Partners (LSP)
+31 20 6645500

Company profile of Life Sciences Partners (LSP)
Past press releases of Life Sciences Partners (LSP).


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Dec 10€2.3MSoftware development
Dec 8€8.5MSoftware development
Dec 8€0.7MGames
Dec 6€5.0MIT services
Dec 5€26.0MEnergy related
Dec 5€5.5MSecurity
Dec 5€16.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!


Press Releases

Aug 17
Komed Health
komed health closes seed financing round

Jul 10
Komed Health
komed health to be supported by nokia and deutsche telekom

May 4
Vivet Therapeutics
vivet therapeutics raises €37.5 million in series a

Apr 5
logistik-start-up fliit sammelt 1.5 millionen bei seed-finanzierung...

Jan 24
in addition to online payments, spendesk is now tackling travel exp...

About usContact usLegal Information
Copyright © 1999-2017
Emerging Technology Research Europe Inc. All rights reserved.